舒洛地特对肺上皮间充质转化的作用研究
|
摘要
特发性肺纤维化(IPF)是一种有着较高病死率的疾病,其特征为肺部成纤维细胞的聚集、大量胶原沉积以及基质重塑。目前人们认为肺泡上皮细胞的上皮-间质转化(epithelial to mesenchymal transition, EMT)这一过程可能在肺纤维化的发病过程中发挥了重要作用,并且TGF-β1可以促进这一过程的发生。糖胺聚糖类药物在临床多用于抗凝,近来越来越多的证据证明以肝素为代表的糖胺聚糖类药物对于器官纤维化有抑制作用。有研究表明其抗纤维化作用可能是通过其对凝血系统激活的抑制产生的,但还有一些研究者发现糖胺聚糖类药物本身也有抗纤维化作用,它们可以抑制TGF-β1在纤维化组织中的过度表达。舒洛地特是从猪小肠粘膜提取的天然物质,由四种糖胺聚糖组成。它与低分子肝素相比有着更少的副作用和更方便的用药方式。目前尚无其对于肺纤维化作用的报道。本研究以体外培养肺上皮A549细胞为基础,通过细胞形态学观察TRF-PCR法以及免疫荧光法检测舒洛地特对于TGF-β1诱导的EMT过程相关标志物表达的影响,来验证舒洛地特在抗凝作用之外的抗纤维化作用。结果显示,舒洛地特能够部分抑制TGF-β1诱导的肺泡上皮细胞形态的变化和间质细胞标志物基因水平和蛋白水平的表达,说明它本身对EMT过程有抑制作用,这也为IPF的治疗提供了一种新的研究方向。
Idiopathic pulmonary fibrosis (IPF) is a disease characterized by fibroblast accumulation, excessive collagen deposition and matrix remodeling which continues to be associated with considerable morbidity and mortality. Now people think the process termed "epithelial-mesenchymal transition"(EMT) may play an important role in fibrogenesis and it has been proved that TGF-β1can induce this process. Nowadays there is compelling evidence that glycosaminoglycans, for example, heparin which are mainly used as anticoagulant can inhibit organ fibrosis. Some researchers found that this kind of medicine may exert their anti fibrotic effect by influencing the activated coagulation cascade. But some people think glycosaminoglycans have their own anti fibrotic effect which is not associated with the haemostatic system, for example, they found that glycosaminoglycans can prevent TGF-β1overexpression in fibrotic tissues. Sulodexide is isolated from porcine intestinal mucosa and comprised of four naturally glycosaminoglycan components. Compared to low-molecular heparin, it has less side effects and can be taken orally. The influence of sulodexide on pulmonary fibrosis has not been studied yet. This study which is based on the culture of human lung epithelial cells A549in vitro used morphology examination, RT-PCR, Immunofluorescence methods to evaluate the effect of Sulodexide on the marker expression in TGF-β1induced EMT process. So it can determine whether it has anti fibrotic activity beyond its anticoagulation effect. The results show the Sulodexide can partially inhibit the morphology changes and decrease the mesenchymal marker expression induced by TGF-β1. This indicate that sulodexide can inhibit the EMT process and it may present a potential novel anti-fibrotic therapeutic approach for the future.
Idiopathic pulmonary fibrosis (IPF) is a disease characterized by fibroblast accumulation, excessive collagen deposition and matrix remodeling which continues to be associated with considerable morbidity and mortality. Now people think the process termed "epithelial-mesenchymal transition"(EMT) may play an important role in fibrogenesis and it has been proved that TGF-β1can induce this process. Nowadays there is compelling evidence that glycosaminoglycans, for example, heparin which are mainly used as anticoagulant can inhibit organ fibrosis. Some researchers found that this kind of medicine may exert their anti fibrotic effect by influencing the activated coagulation cascade. But some people think glycosaminoglycans have their own anti fibrotic effect which is not associated with the haemostatic system, for example, they found that glycosaminoglycans can prevent TGF-β1overexpression in fibrotic tissues. Sulodexide is isolated from porcine intestinal mucosa and comprised of four naturally glycosaminoglycan components. Compared to low-molecular heparin, it has less side effects and can be taken orally. The influence of sulodexide on pulmonary fibrosis has not been studied yet. This study which is based on the culture of human lung epithelial cells A549in vitro used morphology examination, RT-PCR, Immunofluorescence methods to evaluate the effect of Sulodexide on the marker expression in TGF-β1induced EMT process. So it can determine whether it has anti fibrotic activity beyond its anticoagulation effect. The results show the Sulodexide can partially inhibit the morphology changes and decrease the mesenchymal marker expression induced by TGF-β1. This indicate that sulodexide can inhibit the EMT process and it may present a potential novel anti-fibrotic therapeutic approach for the future.
引文
1. Travis WD, King TE Jr, Bateman ED, Lynch DA:American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 2002,265:277-304
2. Du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J Suppl 2001;32:43s-55s
3. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE Jr, Leinwand LA, Liotta L, Martin GR, Schwartz DM, Schultz GS, Wagner CR, Musson RA:Future research directions in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2002,166:236-246
4. Munger JS, Huang X, Kawakatsu H, Griff iths MJD, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al. The integrin α v β 6 binds and activates latent TGF-β1:a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999:96:319-328
5. Selman M, Pardo A:The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003,29:S93-S96
6. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C:Aberrant Wnt/_-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003, 162:1495-1502
7. Raghu Kalluril and Eric G. Neilson2 Epithelial-mesenchymal transition and its implicationsfor fibrosis J. Clin. Invest.2003:112:1776-1784
8. Kevin K. Kim, Matthias C. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix PNAS 2006:4:13180-13185
9. Khali 1 N,O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH (1991) Increased production and immunohistochemical localization of transforming growth factor beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Bio15:155-162
10. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J (1997) Adenovector-mediated gene transfer of active transforming growth factor-betal induces prolonged severe fibrosis in rat lung. J Clin Invest 100:768-776
11. Brigham C. Willis, Janice M. Liebler, Katherine Luby-phelps, Andrew G. Nicholson, Edward D. Crandall, Roland M. du Bois, Zea Borok:Induction of Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells By Transforming Growth Factor-β1; American Journal of Pathology, Vol.166, No 5,May 2005
12. Hidenori Kasai, Jeremy T Allen GF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)Respiratory Research.2005:1186-1465
13. Brigham C. Willisl and Zea Borok.et al TGF-_-induced EMT:mechanisms and implications for fibrotic lung disease Am J Physiol Lung Cell Mol Physiol 293: L525-L534,2007
14. Chri J. Scotton, PhD; and Rachel C. Chambers, PhD. Molecular Targets in Pulmonary Fibrosis. Chest 2007:132:1311-1321
15. Baba M, Snoeck R, Pawles, de Clercq E:Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruases, including herpes simplex, cytomegalovirus, vesicular stomatitis, and human immunodeficiency virus. Antimicrob Agents Chemother 1988,32:1742-1745
16. Nahmias AJ, Kilbrick S:Inhibitory effect of heparin on herpes simplex virus. Am J Pathol 1964,136:683-693
17. Baba M, Pauwels R, Balzarini J, Desmyter J, de Clercq E:Antiviral activity of heparin and dextran sulfate against human immunodeficiency virus (HIV) in vitro. Ann NY Acad Sci1988,556:419-421
18. Dziarski R:Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989,143:356-365
19. McPherson JM, Ledge PW, Ksander G, Sawamura SJ, Conti A, Kincaid S, Michael D, Clark RA:The influence of heparin on the wound healing response to collagen implants in vivo. Collagen Rel Res 1988,1:83-100
20. Andreas Gunther, Norbert Lubke, Monika Ermert, Ralph T. Prevention of Bleomycin-induced Lung Fibrosis By Aerosolization of Heparin or Urokinase in Rabbits. Am J Respir Crit Care Med Vol 168,pp 1358-1365,2003
21. Hiroshi Kubo, MD,FCCP;Katsutoshi Nakayama, MD; Masaru Yanai, MD; Tomoko Suzuki, MD; Mutsuo Yamaya, MD; Mika Watanabe, MD; and Hidetada Sasaki, MD, PhD. Anticoagulant therapy for idiopathic pulmonary fibrosis. CHEST 2005;128:1475-1482
22. S. Frizelle, J. Schwarz, S. A. Huber, K. Leslie. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. American journal of pathology, vol 141, No.1, July 1992
23. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51:59-67
24. Inah M. D. Pecly, Romulo G. Goncalves, Ednei P. Rangel, Christina M. Takiya, Fernanda S. Taboada, Cesonia A. Martinusso, Mauro S. G. Pavao and Mauriol Leite Jr. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronection and TGF-β,and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration Nephrol Dial Transplant(2006)21:1212-1222
25. Guenther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83:853-860.
26. Nakstadt B, Lyberg T, Skjonsberg OH, et al. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57:827-838
27. Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77: 493-504
28. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99:111-117
29. Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156:631-636.
30. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995;1: 932-937
31. Seeger W, Elssner A, Guenther A, et al. Lung surfactant phospholipids associate with polymerizing fibrin-loss of surfactant activity. Am J Respir Cell Mol Biol 1993; 9:213-220.
32. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989; 140:513-524.
33. MONICA CEOL, GIOVANNI GAMBARO, ULRICH SAUER, BRUNO BAGGIO, FRANCA ANGLANI, MONICA FORINO, SONIA FACCHIN, LUCIANA BORDIN, CORA WEIGERT, ANDREAS NERLICH and ERWIND. SCHLEICHER. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
34. Abe W, Ikejima K, Lang T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol 2007,46(2):286-94
35. Zhong Q. Wang, Kaihui H. Liang, Madeleine V. Pahl and Nosratola D. Vaziri. Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Nephrol Dial Transplant(1998)13:3052-3057
36. Ceol M, Gambaro G, Sauer U, et al. Glycosaminoglycan Theray Prevents TGF--β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
37. Hidenori Kasai, Jeremy T Allen GF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)Respiratory Research.2005:1186-1465
38. Selman M, Pardo A:The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003,29:S93-S96
39. Brigham C. Willisl and Zea Borok. et al TGF-_-induced EMT:mechanisms and implications for fibrotic lung disease Am J Physiol Lung Cell Mol Physiol 293: L525-L534,2007
40. Minna Takkunen, Reidar Grenman, Snail-dependent and -independent Epithelial-Mesenchymal Transition in Oral Squamous Carcinoma Cells Journal of Histoche-mistry & Cytochemistry.2006:11:1263-1275
41. Chri J. Scotton, PhD; and Rachel C. Chambers, PhD. Molecular Targets in Pulmonary Fibrosis. Chest 2007:132:1311-1321
42. S. Frizelle, J. Schwarz, S. A. Huber, K. Leslie. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. American journal of pathology, vol 141,No.1, July 1992
43. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51:59-67
44. Inah M. D. Pecly, Romulo G. Goncalves, Ednei P. Rangel, Christina M. Takiya, Fernanda S. Taboada, Cesonia A. Martinusso, Mauro S. G. Pavao and Mauriol Leite Jr. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronection and TGF-p,and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration Nephrol Dial Transplant(2006)21:1212-1222
45. Abe W, Ikejima K, Lang T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol 2007,46(2):286-94
46. Pecly IM, Goncalves RG, Rangel EP, et al. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronectin and TGF-beta, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. Nephrol Dial Transplant 2006,21 (5):1212-22
47. Klinikum Mannheim, Theodor-Kutzer-Ufer. Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide. Med Res. Rev.18, No.1,1-20,1998
48. LUCIANA BORDIN, CORA WEIGERT, ANDREAS NERLICH and ERWIND. SCHLEICHER. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
49. Hidenori Kasai, Jeremy T Allen GF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)Respiratory Research.2005:1186-1465
1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304
2. Andreas Gunther, Norbert Lubke, Monika Ermert, Ralph T. Prevention of Bleomycin-induced Lung Fibrosis By Aerosolization of Heparin or Urokinase in Rabbits. Am J Respir Crit Care Med Vol 168,pp 1358-1365,2003
3. S. Frizelle, J. Schwarz, S. A. Huber, K. Leslie. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. American journal of pathology, vol 141,No.1, July 1992
4. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51:59-67.
5. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7:2495-2508
6. Norman JT, Fine GL. Progressive renal disease:fibroblasts, extracellular matrix and integrins. Exp Nephrol 1999; 7:167-177
7. Muller GA, Zeisberg M, Strutz F. The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant 2000; 6 [Suppl]:S76-S77
8. Schaefer L, Macakova K, Raslik 1 et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002; 160:1181-1191
9. Diamond JR, Ricardo SR, Klahr S. Mechanisms of interstitial fibrosis in obstructive nephropathy. Semin Nephrol 1998; 18:594-602
10. Klahr S, Morrissey JJ. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 1998; 18:622-632
11. Border WA, Noble NA. Targeting TGF-b for treatment of disease. Nat Med 1995; 1: 1000-1001
12. Inah M. D. Pecly, Romulo G. Goncalves, Ednei P. Rangel, Christina M. Takiya, Fernanda S. Taboada, Cesonia A. Martinusso, Mauro S. G. Pavao and Mauriol Leite Jr. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronection and TGF-β, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration Nephrol Dial Transplant(2006)21:1212-1222
13. Hiroshi Kubo, MD, FCCP;Katsutoshi Nakayama, MD; Masaru Yanai, MD; Tomoko Suzuki, MD; Mutsuo Yamaya, MD; Mika Watanabe, MD; and Hidetada Sasaki, MD, PhD. Anticoagulant therapy for idiopathic pulmonary fibrosis. CHEST 2005;128:1475-1482
14. Ehrlich J, Stivala SS. Chemistry and pharmacology of heparin. J Pharm Sci 1973:62:517-544.
15. Jorpes JE. Heparin, its chemistry, pharmacology and clinical use. Am J Med 1962:33:692-702.
16. Noti C, Seeberger PH. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans. Chem Biol 2005;12:731-756.
17. Q. M. ANSTEE, R. D. GOLDIN, M. WRIGHT, A. MARTINELLI, R. COX and M. R. THURSZ Coagulation status modulates murine hepatic fibrogenesis:implications for the development of novel therapies. Journal of Thrombosis and Haemostasis,6:1336-1343
18. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G et al. (2001). Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 159:1383-1395.
19. Yasui H, Gabazza EC, Taguchi 0, Risteli J, Risteli L, Wada H et al. (2000). Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin Appl Thromb Hemost 6:202-205.
20. Kijiyama N, Ueno H, Sugimoto I, Sasaguri Y, Yatera K, Kido M et al. (2006). Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis. Biochem Biophys Res Commun 339:1113-1119.
21. Guenther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83:853-860.
22. Nakstadt B, Lyberg T, Skjonsberg OH, et al. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57:827-838.
23. Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77: 493-504.
24. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99:111-117.
25. Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156:631-636.
26. Hernandez Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM et al. (1995). Role of thrombin in pulmonary fibrosis. Lancet 346:1071-1073.
27. Gu "nther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A et al. (2003). Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 168:1358-1365.
28. Idell S, James KK, Levin EG, et al. Local abnormalities of coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84:695-705.
29. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med1990; 322:890-897.
30. Hasday JD, Bachwich PR, Lynch Ⅲ JP, et al. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 1988; 14:261-278.
31. Idell S, James KK, Gillies C, et al. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135:387-399.
32. Olman MA, Mackman N, Gladson CL, et al. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96:1621-1630.
33. de Waard V, Hansen HR, Spronk HHM, et al. Differential expression of tissue factor mRNA and protein expression in murine sepsis. The role of the granulocyte revisited. Thromb Haemost 2006; 95:348-353.
34. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A (1997). Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 156:631-636.
35. Hernandez Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM et al. (1995). Role of thrombin in pulmonary fibrosis. Lancet 346:1071-1073.
36. Dik WA, Zimmermann LJ, Naber BA, Janssen DJ, Van Kaam AH, Versnel MA (2003). Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant. Pediatr Pulmonol 35:34-41.
37. Peyrol S, Cordier JF, Grimaud JA (1990). Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol 137:155-170.
38. Kobayashi H, Gabazza EC, Taguchi 0, Wada H, Takeya H, Nishioka J et al. (1998). Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med 157:1850-1854.
39. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995;1:932-937.
40. Seeger W, Elssner A, Guenther A, et al. Lung surfactant phospholipids associate with polymerizing fibrin-loss of surfactant activity. Am J Respir Cell Mol Biol 1993; 9:213-220.
41. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989; 140:513-524.
42. Leavell KJ, Peterson MW, Gross TJ, et al. The role of fibrin degradation products in neutrophil recruitment to the lung. Am J Respir Cell Mol Biol 1996; 14:53-60.
43. Dang CV, Bell WR, Kaiser D, et al. Disorganisation of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science 1985; 227:1487-1490.
44. Ciano PS, Colvin RB, Dvorak AM, et al. Macrophage migration in fibrin gel matrix. Lab Invest 1986; 54:62-70.
45. Netzel-Arnett S, Mi tola DJ, Yamada SS, et al. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem.2002; 277:45154-45161.
46. Legrand C, Polette M, Tournier JM, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264:326-336.
47. Okumura Y, Sato H, Seiki M, et al. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 1997; 402:181-184.
48. Yee JA, Yan L, Dominguez JC, et al. Plasminogen dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblastlike cells. J Cell Physiol 1993; 157:528-534.
49. Maquerlot F, Galiacy S, MaloM, et al. Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol.2006;169:1624-1632.
50. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS et al. (2002). Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 168:3577-3585.
51. Howell DC, Johns RH, Lasky JA, et al. Absence of Proteinase-Activated Receptor-1 signalling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166:1353-1365.
52. Baba M, Snoeck R, Pawles, de Clercq E:Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruases, including herpes simplex, cytomegalovirus, vesicular stomatitis, and human immunodeficiency virus. Antimicrob Agents Chemother 1988,32:1742-1745
53. Nahmias AJ, Kilbrick S:Inhibitory effect of heparin on herpes simplex virus. Am J Pathol 1964,136:683-693
54. Baba M, Pauwels R, Balzarini J, Desmyter J, de Clercq E:Antiviral activity of heparin and dextran sulfate against human immunodeficiency virus (HIV) in vitro. Ann NY Acad Sci1988,556:419-421
55. Dziarski R:Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989,143:356-365
56. Sy MS, Schneeberger E, McCluskey R, Green MI, Rosenberg RD Benacerrraf B:Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol1983,82:23-32
57. McPherson JM, Ledge PW, Ksander G, Sawamura SJ, Conti A, Kincaid S, Michael D, Clark RA:The influence of heparin on the wound healing response to collagen implants in vivo. Collagen Rel Res 1988,1:83-100
58. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA:Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818,1993
59. Yang CW, Hattori M, Vlassara H, He CJ, Carome MA, Yamato E, Elliot S, Striker GE, Striker LJ:Overexpression of transforming growth factor b1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 5:1610-1617,1995
60. Gambaro G, Baggio B:Growth factors and the kidney in diabetes mellitus. Crit Rev Clin Lab Sci 35:117-151,1998
61. Sharma K, Ziyadeh FN:Hyperglycemia and diabetic kidney disease:The case for transforming growth factor b as a key mediator. Diabetes 44:1139-1146,1995
62. Miyazono K, Olofsson A, Colosetti P, Heldin CH:A role of the latent TGF-bl binding protein in the assembly and secretion of TGF-bl. EMBO J 10:1091-1101,1991
63. Border WA, Noble NA:Fibrosis linked to TGF-b in yet another disease. J Clin Invest 96:655-656,1995
64. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E:Suppression of experimental glomerulonephritis by antiserum against transforming growth factor b1. Nature (Lond) 346:371-373,1990
65. Sharma K, Jin Y, Guo J, Ziyadeh FN:Neutralization of TGF-b by anti-TGF-b antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530,1996
66. Border WA, Noble NA, Yamamoto T, Tomooka S, Kagami S:Antagonists of transforming growth factor b:A novel approach to treatment of glomerulonephritis and prevention of glomerulonephritis.Kidney Int 65:566-570,1992
67. Border WA:Natural inhibitor of transforming growth factor b protects against scarring in experimental kidney disease. Nature (Lond) 360:361-364,1992
68. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Broder WA:Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418-423,1996
69. Bottinger EP, Factor VM, Tsang MLS, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB:The recombinant proregion of transforming growth factor b1 (latency-associated peptide) inhibits active transforming growth factor in transgenic mice. Proc Natl Acad Sci USA 93:5877-5882,1996
70. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E:Inhibition of TGF-bl expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50:148-155,1996
71. Kashihara N, Maeshina Y, Makino H:Therapeutic intervention in glomerulonephritis by oligonucleotides. Exp Nephrol 5:126-131,1997
72. Kolm V, Sauer U, Olgemoller B, Schleicher E:High glucoseinduced TGF-b1 regulates mesangial production of heparan sulfate proteoglycan. Am J Physiol 270:F812-F821,1996
73. Ziyadeh FN:The extracellular matrix in diabetic nephropathy.Am J Kidney Dis 22: 736-744,1993
74. Osterby R:Glomerular structural changes in type 1 (insulindependent) diabetes mellitus:Causes, consequences, and prevention. Diabetologia 35:803-819,1992
75. Mauer SM, Steffes MW, Ellis EN, Sutherland DN, Brown DM,Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155,1984
76. MONICA CEOL, GIOVANNI GAMBARO, ULRICH SAUER, BRUNO BAGGIO, FRANCA ANGLANI, MONICA FORINO, SONIA FACCHIN, LUCIANA BORDIN, CORA WEIGERT,ANDREAS NERLICH and ERWIND.SCHLEICHER. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
77. Zhong Q. Wang, Kaihui H. Liang, Madeleine V. Pahl and Nosratola D. Vaziri. Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Nephrol Dial Transplant(1998)13:3052-3057
78. Klinikum Mannheim, Theodor-Kutzer-Ufer. Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide. Med Res. Rev.18, No.1,1-20,1998
79. Jacek Karon, Alic ja Polubinska Artur A. Antoniewicz, Katarzyna Suminska-Jasinska Andrzej Breborowicz. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif 2007;25:510-514
80. Borawski J, Dubowski M, Pawlak K. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol 2007,558(1-3):167-171
81. Bottinger EP, Bitzer M. TGF-βSignaling in Renal Disease. J Am Soc Nephrol 2002,13:2600-2610
82. Chaudhuri V, Zhou L, Karasek M. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts:a potential role in skin fibrogenesis. J Gutan Pathol 2007,34(2):146-153
83. Yang J, Dai C,Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005,16(1):68-78
2. Du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J Suppl 2001;32:43s-55s
3. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE Jr, Leinwand LA, Liotta L, Martin GR, Schwartz DM, Schultz GS, Wagner CR, Musson RA:Future research directions in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2002,166:236-246
4. Munger JS, Huang X, Kawakatsu H, Griff iths MJD, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al. The integrin α v β 6 binds and activates latent TGF-β1:a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999:96:319-328
5. Selman M, Pardo A:The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003,29:S93-S96
6. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C:Aberrant Wnt/_-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003, 162:1495-1502
7. Raghu Kalluril and Eric G. Neilson2 Epithelial-mesenchymal transition and its implicationsfor fibrosis J. Clin. Invest.2003:112:1776-1784
8. Kevin K. Kim, Matthias C. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix PNAS 2006:4:13180-13185
9. Khali 1 N,O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH (1991) Increased production and immunohistochemical localization of transforming growth factor beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Bio15:155-162
10. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J (1997) Adenovector-mediated gene transfer of active transforming growth factor-betal induces prolonged severe fibrosis in rat lung. J Clin Invest 100:768-776
11. Brigham C. Willis, Janice M. Liebler, Katherine Luby-phelps, Andrew G. Nicholson, Edward D. Crandall, Roland M. du Bois, Zea Borok:Induction of Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells By Transforming Growth Factor-β1; American Journal of Pathology, Vol.166, No 5,May 2005
12. Hidenori Kasai, Jeremy T Allen GF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)Respiratory Research.2005:1186-1465
13. Brigham C. Willisl and Zea Borok.et al TGF-_-induced EMT:mechanisms and implications for fibrotic lung disease Am J Physiol Lung Cell Mol Physiol 293: L525-L534,2007
14. Chri J. Scotton, PhD; and Rachel C. Chambers, PhD. Molecular Targets in Pulmonary Fibrosis. Chest 2007:132:1311-1321
15. Baba M, Snoeck R, Pawles, de Clercq E:Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruases, including herpes simplex, cytomegalovirus, vesicular stomatitis, and human immunodeficiency virus. Antimicrob Agents Chemother 1988,32:1742-1745
16. Nahmias AJ, Kilbrick S:Inhibitory effect of heparin on herpes simplex virus. Am J Pathol 1964,136:683-693
17. Baba M, Pauwels R, Balzarini J, Desmyter J, de Clercq E:Antiviral activity of heparin and dextran sulfate against human immunodeficiency virus (HIV) in vitro. Ann NY Acad Sci1988,556:419-421
18. Dziarski R:Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989,143:356-365
19. McPherson JM, Ledge PW, Ksander G, Sawamura SJ, Conti A, Kincaid S, Michael D, Clark RA:The influence of heparin on the wound healing response to collagen implants in vivo. Collagen Rel Res 1988,1:83-100
20. Andreas Gunther, Norbert Lubke, Monika Ermert, Ralph T. Prevention of Bleomycin-induced Lung Fibrosis By Aerosolization of Heparin or Urokinase in Rabbits. Am J Respir Crit Care Med Vol 168,pp 1358-1365,2003
21. Hiroshi Kubo, MD,FCCP;Katsutoshi Nakayama, MD; Masaru Yanai, MD; Tomoko Suzuki, MD; Mutsuo Yamaya, MD; Mika Watanabe, MD; and Hidetada Sasaki, MD, PhD. Anticoagulant therapy for idiopathic pulmonary fibrosis. CHEST 2005;128:1475-1482
22. S. Frizelle, J. Schwarz, S. A. Huber, K. Leslie. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. American journal of pathology, vol 141, No.1, July 1992
23. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51:59-67
24. Inah M. D. Pecly, Romulo G. Goncalves, Ednei P. Rangel, Christina M. Takiya, Fernanda S. Taboada, Cesonia A. Martinusso, Mauro S. G. Pavao and Mauriol Leite Jr. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronection and TGF-β,and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration Nephrol Dial Transplant(2006)21:1212-1222
25. Guenther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83:853-860.
26. Nakstadt B, Lyberg T, Skjonsberg OH, et al. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57:827-838
27. Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77: 493-504
28. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99:111-117
29. Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156:631-636.
30. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995;1: 932-937
31. Seeger W, Elssner A, Guenther A, et al. Lung surfactant phospholipids associate with polymerizing fibrin-loss of surfactant activity. Am J Respir Cell Mol Biol 1993; 9:213-220.
32. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989; 140:513-524.
33. MONICA CEOL, GIOVANNI GAMBARO, ULRICH SAUER, BRUNO BAGGIO, FRANCA ANGLANI, MONICA FORINO, SONIA FACCHIN, LUCIANA BORDIN, CORA WEIGERT, ANDREAS NERLICH and ERWIND. SCHLEICHER. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
34. Abe W, Ikejima K, Lang T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol 2007,46(2):286-94
35. Zhong Q. Wang, Kaihui H. Liang, Madeleine V. Pahl and Nosratola D. Vaziri. Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Nephrol Dial Transplant(1998)13:3052-3057
36. Ceol M, Gambaro G, Sauer U, et al. Glycosaminoglycan Theray Prevents TGF--β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
37. Hidenori Kasai, Jeremy T Allen GF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)Respiratory Research.2005:1186-1465
38. Selman M, Pardo A:The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003,29:S93-S96
39. Brigham C. Willisl and Zea Borok. et al TGF-_-induced EMT:mechanisms and implications for fibrotic lung disease Am J Physiol Lung Cell Mol Physiol 293: L525-L534,2007
40. Minna Takkunen, Reidar Grenman, Snail-dependent and -independent Epithelial-Mesenchymal Transition in Oral Squamous Carcinoma Cells Journal of Histoche-mistry & Cytochemistry.2006:11:1263-1275
41. Chri J. Scotton, PhD; and Rachel C. Chambers, PhD. Molecular Targets in Pulmonary Fibrosis. Chest 2007:132:1311-1321
42. S. Frizelle, J. Schwarz, S. A. Huber, K. Leslie. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. American journal of pathology, vol 141,No.1, July 1992
43. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51:59-67
44. Inah M. D. Pecly, Romulo G. Goncalves, Ednei P. Rangel, Christina M. Takiya, Fernanda S. Taboada, Cesonia A. Martinusso, Mauro S. G. Pavao and Mauriol Leite Jr. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronection and TGF-p,and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration Nephrol Dial Transplant(2006)21:1212-1222
45. Abe W, Ikejima K, Lang T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol 2007,46(2):286-94
46. Pecly IM, Goncalves RG, Rangel EP, et al. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronectin and TGF-beta, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. Nephrol Dial Transplant 2006,21 (5):1212-22
47. Klinikum Mannheim, Theodor-Kutzer-Ufer. Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide. Med Res. Rev.18, No.1,1-20,1998
48. LUCIANA BORDIN, CORA WEIGERT, ANDREAS NERLICH and ERWIND. SCHLEICHER. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
49. Hidenori Kasai, Jeremy T Allen GF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)Respiratory Research.2005:1186-1465
1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304
2. Andreas Gunther, Norbert Lubke, Monika Ermert, Ralph T. Prevention of Bleomycin-induced Lung Fibrosis By Aerosolization of Heparin or Urokinase in Rabbits. Am J Respir Crit Care Med Vol 168,pp 1358-1365,2003
3. S. Frizelle, J. Schwarz, S. A. Huber, K. Leslie. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. American journal of pathology, vol 141,No.1, July 1992
4. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51:59-67.
5. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7:2495-2508
6. Norman JT, Fine GL. Progressive renal disease:fibroblasts, extracellular matrix and integrins. Exp Nephrol 1999; 7:167-177
7. Muller GA, Zeisberg M, Strutz F. The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant 2000; 6 [Suppl]:S76-S77
8. Schaefer L, Macakova K, Raslik 1 et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002; 160:1181-1191
9. Diamond JR, Ricardo SR, Klahr S. Mechanisms of interstitial fibrosis in obstructive nephropathy. Semin Nephrol 1998; 18:594-602
10. Klahr S, Morrissey JJ. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 1998; 18:622-632
11. Border WA, Noble NA. Targeting TGF-b for treatment of disease. Nat Med 1995; 1: 1000-1001
12. Inah M. D. Pecly, Romulo G. Goncalves, Ednei P. Rangel, Christina M. Takiya, Fernanda S. Taboada, Cesonia A. Martinusso, Mauro S. G. Pavao and Mauriol Leite Jr. Effects of low molecular weight heparin in obstructed kidneys:decrease of collagen, fibronection and TGF-β, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration Nephrol Dial Transplant(2006)21:1212-1222
13. Hiroshi Kubo, MD, FCCP;Katsutoshi Nakayama, MD; Masaru Yanai, MD; Tomoko Suzuki, MD; Mutsuo Yamaya, MD; Mika Watanabe, MD; and Hidetada Sasaki, MD, PhD. Anticoagulant therapy for idiopathic pulmonary fibrosis. CHEST 2005;128:1475-1482
14. Ehrlich J, Stivala SS. Chemistry and pharmacology of heparin. J Pharm Sci 1973:62:517-544.
15. Jorpes JE. Heparin, its chemistry, pharmacology and clinical use. Am J Med 1962:33:692-702.
16. Noti C, Seeberger PH. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans. Chem Biol 2005;12:731-756.
17. Q. M. ANSTEE, R. D. GOLDIN, M. WRIGHT, A. MARTINELLI, R. COX and M. R. THURSZ Coagulation status modulates murine hepatic fibrogenesis:implications for the development of novel therapies. Journal of Thrombosis and Haemostasis,6:1336-1343
18. Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G et al. (2001). Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 159:1383-1395.
19. Yasui H, Gabazza EC, Taguchi 0, Risteli J, Risteli L, Wada H et al. (2000). Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin Appl Thromb Hemost 6:202-205.
20. Kijiyama N, Ueno H, Sugimoto I, Sasaguri Y, Yatera K, Kido M et al. (2006). Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis. Biochem Biophys Res Commun 339:1113-1119.
21. Guenther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83:853-860.
22. Nakstadt B, Lyberg T, Skjonsberg OH, et al. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57:827-838.
23. Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77: 493-504.
24. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99:111-117.
25. Imokawa S, Sato A, Hayakawa H, et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156:631-636.
26. Hernandez Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM et al. (1995). Role of thrombin in pulmonary fibrosis. Lancet 346:1071-1073.
27. Gu "nther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A et al. (2003). Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 168:1358-1365.
28. Idell S, James KK, Levin EG, et al. Local abnormalities of coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84:695-705.
29. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med1990; 322:890-897.
30. Hasday JD, Bachwich PR, Lynch Ⅲ JP, et al. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 1988; 14:261-278.
31. Idell S, James KK, Gillies C, et al. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135:387-399.
32. Olman MA, Mackman N, Gladson CL, et al. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96:1621-1630.
33. de Waard V, Hansen HR, Spronk HHM, et al. Differential expression of tissue factor mRNA and protein expression in murine sepsis. The role of the granulocyte revisited. Thromb Haemost 2006; 95:348-353.
34. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A (1997). Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 156:631-636.
35. Hernandez Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM et al. (1995). Role of thrombin in pulmonary fibrosis. Lancet 346:1071-1073.
36. Dik WA, Zimmermann LJ, Naber BA, Janssen DJ, Van Kaam AH, Versnel MA (2003). Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant. Pediatr Pulmonol 35:34-41.
37. Peyrol S, Cordier JF, Grimaud JA (1990). Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol 137:155-170.
38. Kobayashi H, Gabazza EC, Taguchi 0, Wada H, Takeya H, Nishioka J et al. (1998). Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med 157:1850-1854.
39. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995;1:932-937.
40. Seeger W, Elssner A, Guenther A, et al. Lung surfactant phospholipids associate with polymerizing fibrin-loss of surfactant activity. Am J Respir Cell Mol Biol 1993; 9:213-220.
41. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989; 140:513-524.
42. Leavell KJ, Peterson MW, Gross TJ, et al. The role of fibrin degradation products in neutrophil recruitment to the lung. Am J Respir Cell Mol Biol 1996; 14:53-60.
43. Dang CV, Bell WR, Kaiser D, et al. Disorganisation of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science 1985; 227:1487-1490.
44. Ciano PS, Colvin RB, Dvorak AM, et al. Macrophage migration in fibrin gel matrix. Lab Invest 1986; 54:62-70.
45. Netzel-Arnett S, Mi tola DJ, Yamada SS, et al. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem.2002; 277:45154-45161.
46. Legrand C, Polette M, Tournier JM, et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264:326-336.
47. Okumura Y, Sato H, Seiki M, et al. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 1997; 402:181-184.
48. Yee JA, Yan L, Dominguez JC, et al. Plasminogen dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblastlike cells. J Cell Physiol 1993; 157:528-534.
49. Maquerlot F, Galiacy S, MaloM, et al. Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol.2006;169:1624-1632.
50. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS et al. (2002). Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 168:3577-3585.
51. Howell DC, Johns RH, Lasky JA, et al. Absence of Proteinase-Activated Receptor-1 signalling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166:1353-1365.
52. Baba M, Snoeck R, Pawles, de Clercq E:Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruases, including herpes simplex, cytomegalovirus, vesicular stomatitis, and human immunodeficiency virus. Antimicrob Agents Chemother 1988,32:1742-1745
53. Nahmias AJ, Kilbrick S:Inhibitory effect of heparin on herpes simplex virus. Am J Pathol 1964,136:683-693
54. Baba M, Pauwels R, Balzarini J, Desmyter J, de Clercq E:Antiviral activity of heparin and dextran sulfate against human immunodeficiency virus (HIV) in vitro. Ann NY Acad Sci1988,556:419-421
55. Dziarski R:Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989,143:356-365
56. Sy MS, Schneeberger E, McCluskey R, Green MI, Rosenberg RD Benacerrraf B:Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol1983,82:23-32
57. McPherson JM, Ledge PW, Ksander G, Sawamura SJ, Conti A, Kincaid S, Michael D, Clark RA:The influence of heparin on the wound healing response to collagen implants in vivo. Collagen Rel Res 1988,1:83-100
58. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA:Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818,1993
59. Yang CW, Hattori M, Vlassara H, He CJ, Carome MA, Yamato E, Elliot S, Striker GE, Striker LJ:Overexpression of transforming growth factor b1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 5:1610-1617,1995
60. Gambaro G, Baggio B:Growth factors and the kidney in diabetes mellitus. Crit Rev Clin Lab Sci 35:117-151,1998
61. Sharma K, Ziyadeh FN:Hyperglycemia and diabetic kidney disease:The case for transforming growth factor b as a key mediator. Diabetes 44:1139-1146,1995
62. Miyazono K, Olofsson A, Colosetti P, Heldin CH:A role of the latent TGF-bl binding protein in the assembly and secretion of TGF-bl. EMBO J 10:1091-1101,1991
63. Border WA, Noble NA:Fibrosis linked to TGF-b in yet another disease. J Clin Invest 96:655-656,1995
64. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E:Suppression of experimental glomerulonephritis by antiserum against transforming growth factor b1. Nature (Lond) 346:371-373,1990
65. Sharma K, Jin Y, Guo J, Ziyadeh FN:Neutralization of TGF-b by anti-TGF-b antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530,1996
66. Border WA, Noble NA, Yamamoto T, Tomooka S, Kagami S:Antagonists of transforming growth factor b:A novel approach to treatment of glomerulonephritis and prevention of glomerulonephritis.Kidney Int 65:566-570,1992
67. Border WA:Natural inhibitor of transforming growth factor b protects against scarring in experimental kidney disease. Nature (Lond) 360:361-364,1992
68. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Broder WA:Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418-423,1996
69. Bottinger EP, Factor VM, Tsang MLS, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB:The recombinant proregion of transforming growth factor b1 (latency-associated peptide) inhibits active transforming growth factor in transgenic mice. Proc Natl Acad Sci USA 93:5877-5882,1996
70. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E:Inhibition of TGF-bl expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50:148-155,1996
71. Kashihara N, Maeshina Y, Makino H:Therapeutic intervention in glomerulonephritis by oligonucleotides. Exp Nephrol 5:126-131,1997
72. Kolm V, Sauer U, Olgemoller B, Schleicher E:High glucoseinduced TGF-b1 regulates mesangial production of heparan sulfate proteoglycan. Am J Physiol 270:F812-F821,1996
73. Ziyadeh FN:The extracellular matrix in diabetic nephropathy.Am J Kidney Dis 22: 736-744,1993
74. Osterby R:Glomerular structural changes in type 1 (insulindependent) diabetes mellitus:Causes, consequences, and prevention. Diabetologia 35:803-819,1992
75. Mauer SM, Steffes MW, Ellis EN, Sutherland DN, Brown DM,Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155,1984
76. MONICA CEOL, GIOVANNI GAMBARO, ULRICH SAUER, BRUNO BAGGIO, FRANCA ANGLANI, MONICA FORINO, SONIA FACCHIN, LUCIANA BORDIN, CORA WEIGERT,ANDREAS NERLICH and ERWIND.SCHLEICHER. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11:2324-2336,2000
77. Zhong Q. Wang, Kaihui H. Liang, Madeleine V. Pahl and Nosratola D. Vaziri. Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Nephrol Dial Transplant(1998)13:3052-3057
78. Klinikum Mannheim, Theodor-Kutzer-Ufer. Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide. Med Res. Rev.18, No.1,1-20,1998
79. Jacek Karon, Alic ja Polubinska Artur A. Antoniewicz, Katarzyna Suminska-Jasinska Andrzej Breborowicz. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif 2007;25:510-514
80. Borawski J, Dubowski M, Pawlak K. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol 2007,558(1-3):167-171
81. Bottinger EP, Bitzer M. TGF-βSignaling in Renal Disease. J Am Soc Nephrol 2002,13:2600-2610
82. Chaudhuri V, Zhou L, Karasek M. Inflammatory cytokines induce the transformation of human dermal microvascular endothelial cells into myofibroblasts:a potential role in skin fibrogenesis. J Gutan Pathol 2007,34(2):146-153
83. Yang J, Dai C,Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005,16(1):68-78